Blood test–guided extra treatment for colon cancer recurrence risk
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 1 study uses a blood test called ctDNA to decide whether and how to adjust treatment in people with colon cancer who still have a small amount of disease left after surgery. If your blood test remains positive, the trial aims to reduce recurrence risk by guiding treatment changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed colon adenocarcinoma (or certain colon-cancer–type tumors treated like colon cancer after surgery).
- Your cancer is Stage II, III, or IV after surgery done with cure intent, and you started (and finished at least 3 months of) standard after-surgery chemotherapy.
- Your ctDNA blood test (Signatera MRD) is positive at least 3 months after finishing perioperative chemotherapy.
- You must be 18 or older, able to swallow pills, and well enough to do daily activities (ECOG 0–2).
- You cannot be recently treated or not recovered: no major surgery in the last 4 weeks, and no chemotherapy or radiation within 2 weeks.
- You must use effective birth control if pregnancy is possible, and you must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a simple blood test to look for tiny bits of tumor DNA after colon cancer surgery. If found, it may help doctors catch any remaining cancer early and guide further treatment.
This Phase 2 study tests the best way to choose and then follow treatment when colorectal cancer has spread only to a small number of spots. You may be eligible if your doctors can remove or precisely treat the spots and there’s no sign of additional spread on scans.
This trial tests a drug called AMB-05X for people with colorectal cancer who have completed all intended treatments and show no signs of cancer on scans, but still have cancer DNA (ctDNA) in their blood. The goal is to see if AMB-05X can eliminate this remaining cancer DNA and prevent the cancer from coming back.
This trial tests a personalized immune therapy (like a custom vaccine) for people with colorectal cancer that has a positive ctDNA MRD test after surgery. It aims to use the body's own immune system to target any remaining cancer cells and prevent the cancer from coming back.
This trial tests a new drug, Telisotuzumab Adizutecan, given through a vein (infusion) alone or with standard treatments for people with colorectal cancer who have no visible tumors on scans but still have cancer DNA (ctDNA) in their blood after surgery and chemotherapy.
This study uses a simple blood test to detect cancer DNA after surgery for early-stage colon cancer. The goal is to help doctors decide whether chemotherapy is truly needed based on the blood test results, rather than giving it to everyone.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.